MyoKardia (MYOK) reported earnings on Thur 2 Nov 2017 (b/o)

** charts after earnings **

MyoKardia reports EPS in-line, misses on revs 

• Reports Q3 (Sep) loss of $0.42 per share, in-linewith the Capital IQ Consensus of ($0.42); revenues rose 58.6% year/year to $5.63 mln vs the $6.1 mln Capital IQ Consensus.
• Cash and cash equivalents as of September 30, 2017 were $227.2 million, compared to $135.8 million as of December 31, 2016. 

MyoKardia (MYOK) : positive mid-stage trial results for heart muscle disease

  

MyoKardia Inc. (MYOK) surged on positive mid-stage clinical trial results for its mavacamten therapy. Patients on the therapy met the trial's primary endpoint and key secondary endpoints in the phase 2 trial, the company said. MyoKardia expects to start its next clinical trial by the end of this year, depending on discussions with the Food and Drug Administration. The latest data came from the clinical trial's first patient cohort, in which 11 patients were enrolled and 10 patients completed the study. The one patient in question had a history of atrial fibrillation and experienced an episode of atrial fibrillation during the trial. All other safety problems were mild to moderate, according to MyoKardia, and "a majority of the [adverse events] were deemed to be unrelated to the study drug." The Independent Data Monitoring Committee reviewed the trial's safety data and recommended the study be continued, the company said. Mavacamten is intended for symptomatic, obstructive hypertrophic cardiomyopathy, which occurs when heart muscle cells enlarge and block blood flow, and is a common cause of sudden cardiac arrest, according to the American Heart Association. MyoKardia shares have surged 20.4% over the last three months, compared with a 3.2% rise in the S&P 500 (SPX).

MyoKardia (MYOK) started trading on the Nasdaq on 29 October 2015

• MyoKardia (NASDAQ:MYOK) offered 5,437,500 shares of common stock at $10 per share. Underwriters over-allotment is an additional 815,625 shares. Closing date is November 3.
• The original IPO was 4,687,500 shares at $15 - 17.
• Previously: MyoKardia set for IPO (Oct. 22)
• MyoKardia offers a valuable solution in a distinct market but the company is only in Phase 1 of testing its first therapies.
• MyoKardia predicted bringing home $91.6 million with its IPO. The company’s take home was only $54 million.

  

  

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Address

333 Allerton Ave
SOUTH SAN FRANCISCO, CA 94080-4816
United States 

Website 

http://www.myokardia.com

Key stats and ratios

	Q2 (Jun '17)	2016
Net profit margin	-228.21%	-33.55%
Operating margin	-233.71%	-33.94%
EBITD margin	-	-31.11%
Return on average assets	-29.08%	-8.27%
Return on average equity	-39.69%	-10.99%
Employees	78